IVVD

Invivyd, Inc. NASDAQ Listed Aug 6, 2021

Healthcare ·Biotechnology ·US · adagiotx.com

$1.46

After hrs $1.48 +1.37%

Mkt Cap $193.8M

52w Low $0.48 37.8% of range 52w High $3.07

50d MA $1.57 200d MA $1.64

P/E (TTM) -5.1x

EV/EBITDA -3.8x

P/B 1.1x

Debt/Equity 0.0x

ROE -21.7%

P/FCF -7.3x

RSI (14) —

ATR (14) —

Beta 0.74

50d MA $1.57

200d MA $1.64

Avg Volume 2.8M

About

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Thera…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 5, 2026	AMC	-0.06	0.02	+133.3%	1.74	-2.3%	+3.4%	+8.6%	+5.2%	+9.2%	+3.4%	—
Nov 6, 2025	AMC	-0.05	-0.06	-20.0%	1.54	-3.9%	+3.2%	+4.5%	+7.1%	+14.9%	+14.9%	—
Aug 14, 2025	AMC	-0.04	-0.12	-200.0%	0.80	-10.3%	-11.5%	-27.3%	-28.6%	-20.7%	-34.0%	—
May 15, 2025	AMC	-0.04	-0.14	-250.0%	0.70	-0.3%	+10.3%	+10.2%	+14.9%	+8.6%	+8.0%	—
Mar 20, 2025	AMC	-0.25	-0.15	+40.0%	0.74	+3.3%	-0.1%	-2.0%	-10.7%	-16.7%	-17.4%	—
Nov 14, 2024	AMC	-0.33	-0.51	-54.5%	0.79	+3.7%	-4.5%	-6.4%	-2.9%	-2.8%	-11.5%	—
Aug 14, 2024	AMC	-0.37	-0.40	-8.1%	0.98	+0.0%	+6.1%	-0.4%	-6.8%	-11.9%	-10.4%	—
May 9, 2024	AMC	-0.51	-0.38	+25.5%	2.42	-0.8%	-6.6%	-2.1%	+0.4%	+1.7%	+1.2%	—
Mar 28, 2024	AMC	-0.41	-0.67	-63.4%	4.44	+5.9%	-4.3%	-14.2%	-11.5%	-19.4%	-25.7%	—
Nov 9, 2023	AMC	-0.54	-0.36	+33.3%	1.40	+2.1%	+0.0%	+7.1%	+7.1%	+5.7%	+7.1%	—
Aug 10, 2023	AMC	-0.40	-0.46	-15.0%	1.55	+3.2%	+3.2%	+3.2%	+5.8%	+7.1%	+10.3%	—
May 11, 2023	AMC	-0.36	-0.32	+11.1%	1.43	+0.0%	+0.7%	+7.0%	+4.9%	+6.3%	-12.6%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Feb 26	BTIG	Maintains	Buy → Buy	—	$1.71	$1.73	+1.2%	-0.6%	-1.2%	+0.6%	-5.3%	+0.0%
Dec 23	BTIG	Maintains	Buy → Buy	—	$2.88	$2.90	+0.7%	-2.8%	-2.4%	-6.6%	-10.1%	-15.6%
Nov 25	D. Boral Capital	Downgrade	Buy → Hold	—	$2.40	$2.34	-2.5%	-5.4%	-2.9%	+1.2%	+4.2%	-10.0%
Nov 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.76	$1.80	+2.3%	-8.5%	-20.5%	-13.6%	-12.5%	-9.7%
Oct 31	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.87	$1.86	-0.5%	-5.9%	-13.9%	-25.1%	-18.7%	-17.6%
Oct 6	D. Boral Capital	Maintains	Buy → Buy	—	$1.16	$1.29	+11.2%	+22.4%	+40.5%	+41.4%	+62.9%	+51.7%
Aug 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.03	$1.02	-1.0%	-15.4%	-3.9%	-5.5%	+0.0%	+1.0%
Aug 25	D. Boral Capital	Maintains	Buy → Buy	—	$0.52	$0.53	+2.6%	+7.6%	+98.0%	+67.5%	+90.3%	+87.1%
Aug 19	D. Boral Capital	Maintains	Buy → Buy	—	$0.58	$0.59	+2.4%	-1.7%	+9.1%	-9.2%	-10.5%	-3.7%
Aug 15	D. Boral Capital	Maintains	Buy → Buy	—	$0.80	$0.72	-10.3%	-11.5%	-27.3%	-28.6%	-20.7%	-34.0%
Jun 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.70	$0.73	+4.2%	+13.4%	+3.2%	+1.5%	+2.4%	+2.7%
Jun 26	D. Boral Capital	Maintains	Buy → Buy	—	$0.70	$0.73	+4.2%	+13.4%	+3.2%	+1.5%	+2.4%	+2.7%
May 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.90	$0.89	-1.0%	-6.0%	-5.7%	+4.0%	+3.4%	+7.5%
May 16	D. Boral Capital	Maintains	Buy → Buy	—	$0.70	$0.70	-0.3%	+10.3%	+10.2%	+14.9%	+8.6%	+8.0%
Mar 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.66	$0.67	+1.6%	-6.7%	-7.5%	-9.0%	-8.2%	-18.1%
Mar 20	D. Boral Capital	Maintains	Buy → Buy	—	$0.72	$0.72	+0.4%	+2.6%	+2.5%	+0.6%	-8.4%	-14.5%
Mar 5	D. Boral Capital	Maintains	Buy → Buy	—	$1.05	$1.15	+9.5%	+1.0%	-1.9%	-3.8%	-12.9%	-19.4%
Feb 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.77	$1.30	-26.6%	-29.9%	-26.6%	-30.5%	-29.9%	-34.5%
Feb 24	D. Boral Capital	Maintains	Buy → Buy	—	$1.77	$1.30	-26.6%	-29.9%	-26.6%	-30.5%	-29.9%	-34.5%
Feb 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.06	$1.26	+18.9%	+17.9%	+99.1%	+86.8%	+92.5%	+48.1%
Feb 3	D. Boral Capital	Maintains	Buy → Buy	—	$0.36	$0.44	+24.2%	+196.3%	+249.5%	+489.9%	+453.5%	+470.3%
Jan 27	D. Boral Capital	Maintains	Buy → Buy	—	$0.47	$0.46	-2.2%	-12.9%	-12.5%	-18.5%	-17.5%	-24.4%
Jan 10	D. Boral Capital	Maintains	Buy → Buy	—	$0.46	$0.46	-0.3%	-2.1%	-13.5%	-12.3%	-10.5%	-4.8%
Nov 21	D. Boral Capital	Maintains	Buy → Buy	—	$0.77	$0.76	-0.6%	-8.9%	-8.7%	-12.7%	-23.2%	-12.2%
Nov 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.77	$0.76	-0.5%	+0.1%	-8.8%	-8.6%	-12.7%	-23.1%
Nov 20	Morgan Stanley	Maintains	Overweight → Overweight	—	$0.77	$0.76	-0.5%	+0.1%	-8.8%	-8.6%	-12.7%	-23.1%
Nov 14	D. Boral Capital	Maintains	Buy → Buy	—	$0.89	$0.89	+0.0%	-11.2%	-15.2%	-16.9%	-13.8%	-13.7%
Oct 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.04	$1.01	-2.9%	-12.8%	-12.5%	-14.2%	-12.2%	-13.5%
Sep 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.85	$0.86	+1.2%	+0.2%	-0.0%	+0.1%	-4.3%	+6.0%
Aug 30	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.88	$0.90	+1.9%	-3.8%	-3.6%	-3.8%	-3.6%	-7.9%
Aug 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.29	$1.29	+0.0%	-28.7%	-30.2%	-31.5%	-34.1%	-34.0%
May 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.01	$2.00	-0.5%	-4.0%	-12.4%	-16.4%	-10.0%	-8.5%
May 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.37	$2.37	+0.0%	+2.5%	+3.8%	+3.4%	+1.3%	-5.1%
Apr 5	Guggenheim	Upgrade	Neutral → Buy	—	$3.58	$3.77	+5.3%	-7.8%	-14.5%	-15.6%	-15.9%	-14.5%
Mar 26	Morgan Stanley	Upgrade	Equal Weight → Overweight	—	$3.23	$3.87	+19.8%	+13.3%	+23.8%	+37.5%	+31.6%	+18.0%
Mar 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.36	$4.02	-7.8%	-25.9%	-16.1%	-8.3%	+1.8%	-2.5%
Jan 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.12	$4.51	+9.5%	+7.8%	+14.1%	+9.2%	+8.3%	+7.5%
Dec 19	Morgan Stanley	Upgrade	Underweight → Equal Weight	—	$3.59	$2.96	-17.5%	-7.5%	-5.0%	+4.5%	+8.1%	+1.7%
Aug 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.60	$1.56	-2.5%	+0.0%	+2.5%	+3.8%	+6.9%	-1.9%
Jul 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.39	$1.41	+1.4%	-1.4%	-2.9%	+4.3%	+5.0%	+0.7%
Jun 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.06	$1.03	-2.8%	+0.9%	-0.9%	+5.7%	+12.3%	+6.6%
May 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.44	$1.45	+0.7%	+6.2%	+4.2%	+5.6%	-13.2%	-13.9%
Mar 27	Morgan Stanley	Maintains	Underweight → Underweight	—	$1.31	$1.28	-2.3%	+6.5%	+3.1%	-1.5%	-9.5%	-8.4%
Jan 24	Morgan Stanley	Maintains	Underweight → Underweight	—	$2.04	$2.02	-1.0%	+7.8%	+18.6%	+17.2%	+21.6%	+11.3%
Sep 16	Morgan Stanley	Maintains	Underweight → Underweight	—	$4.07	$4.02	-1.2%	-5.7%	-12.3%	-15.5%	-19.2%	-19.7%
Sep 14	Morgan Stanley	Maintains	Underweight → Underweight	—	$4.83	$4.65	-3.7%	-9.3%	-15.7%	-20.5%	-26.1%	-28.8%
May 16	Morgan Stanley	Maintains	Underweight → Underweight	—	$2.72	$2.74	+0.7%	+5.5%	+12.5%	+8.5%	+9.2%	+8.5%
Jan 5	Morgan Stanley	Downgrade	Equal Weight → Underweight	—	$7.22	$6.96	-3.6%	-10.0%	-15.2%	-17.9%	-15.4%	-16.6%
Dec 21	Jefferies	Downgrade	Buy → Hold	—	$10.00	$9.65	-3.5%	+2.9%	-10.9%	-13.4%	-10.0%	-21.5%
Dec 14	Guggenheim	Downgrade	Buy → Neutral	—	$34.26	$10.00	-70.8%	-78.8%	-81.5%	-58.6%	-66.5%	-70.8%

Recent Filings

8-K · 8.01 !! High

Unknown — 8-K 8.01: Material Event / Announcement

Invivyd's pipeline expansion with a potential first-in-class measles antibody and clinical progress on COVID-19 candidate could justify premium valuation if development succeeds, but investors should monitor clinical trial results carefully.

Apr 9

8-K · 8.01 !! High

Invivyd, Inc. -- 8-K 8.01: Material Event / Announcement

Invivyd updated its corporate presentation on March 5, 2026, providing investors with current information about the company's business strategy and operations.

Mar 5

Data updated apr 25, 2026 4:32pm · Source: massive.com